Isomab Ltd. has nominated ISM-001 as a development candidate for peripheral arterial disease. ISM-001 is a potential first-in-class therapeutic antibody designed to neutralize VEGF-A165b, the ...
The global pulmonary arterial hypertension treatment market is on track to achieve significant growth over the next decade, with a projected valuation of USD 7,224.4 million by 2033. This expansion ...